Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies.
about
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Intraclonal genome diversity of Pseudomonas aeruginosa clones CHA and TBThe fatty acid signaling molecule cis-2-decenoic acid increases metabolic activity and reverts persister cells to an antimicrobial-susceptible state.A proteomic approach to understand the role of the outer membrane porins in the organic solvent-tolerance of Pseudomonas aeruginosa PseAPredicting Antimicrobial Resistance Prevalence and Incidence from Indicators of Antimicrobial Use: What Is the Most Accurate Indicator for Surveillance in Intensive Care Units?Silver-coated carbon nanotubes downregulate the expression of Pseudomonas aeruginosa virulence genes: a potential mechanism for their antimicrobial effect.Mutational and acquired carbapenem resistance mechanisms in multidrug resistant Pseudomonas aeruginosa clinical isolates from Recife, BrazilOprD Repression upon Metal Treatment Requires the RNA Chaperone Hfq in Pseudomonas aeruginosa.Study on the resistance mechanism via outer membrane protein OprD2 and metal β-lactamase expression in the cell wall of Pseudomonas aeruginosa.Fit and resistant is a worst case scenario with bacterial pathogensImipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates.Pseudomonas aeruginosa: targeting cell-wall metabolism for new antibacterial discovery and development.Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy.Global Dynamic Proteome Study of a Pellicle-forming Acinetobacter baumannii Strain.Probing the binding affinities of imipenem and ertapenem for outer membrane carboxylate channel D1 (OccD1) from P. aeruginosa: simulation studies.Identification of outer membrane Porin D as a vitronectin-binding factor in cystic fibrosis clinical isolates of Pseudomonas aeruginosa.Molecular Epidemiology of Mutations in Antimicrobial Resistance Loci of Pseudomonas aeruginosa Isolates from Airways of Cystic Fibrosis Patients.Characterization of clinical extensively drug-resistant Pseudomonas aeruginosa in the Hunan province of ChinaN-acetylcysteine selectively antagonizes the activity of imipenem in Pseudomonas aeruginosa by an OprD-mediated mechanism.Upregulated effects of miR-7 in methicillin-resistant Staphylococcus aureusExploring bacterial outer membrane barrier to combat bad bugs.Pseudomonas aeruginosa Genome Evolution in Patients and under the Hospital Environment.Antimicrobial Effect of Imipenem-Functionalized Fe2O3 Nanoparticles on Pseudomonas aeruginosa Producing Metallo β-lactamases.Molecular epidemiology and mechanisms of antimicrobial resistance in Pseudomonas aeruginosa isolates causing burn wound infection in Iran.Comparative genomics of a drug-resistant Pseudomonas aeruginosa panel and the challenges of antimicrobial resistance prediction from genomes.Multicentre investigation of pathogenic bacteria and antibiotic resistance genes in Chinese patients with acute exacerbation of chronic obstructive pulmonary disease.Prevalence and antibiotic resistance of Pseudomonas aeruginosa in water samples in central Italy and molecular characterization of oprD in imipenem resistant isolates.Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.Probing the sRNA regulatory landscape of P. aeruginosa: post-transcriptional control of determinants of pathogenicity and antibiotic susceptibility.The investigation of different pollutants and operation processes on sludge toxicity in sequencing batch bioreactors.Molecular Typing and Carbapenem Resistance Mechanisms of Pseudomonas aeruginosa Isolated From a Chinese Burn Center From 2011 to 2016.Interplay between MexAB-OprM and MexEF-OprN in clinical isolates of Pseudomonas aeruginosaThe Simplified Carbapenem Inactivation Method (sCIM) for Simple and Accurate Detection of Carbapenemase-Producing Gram-Negative Bacilli
P2860
Q26739860-55D87885-A636-4F85-A717-9CEA30786882Q31121749-4DE09F6E-659D-4B09-BE16-1E13231C5362Q34594203-D53FDAA8-C6B3-4988-96EE-92606B13675BQ35218407-EE0B9FE3-F52C-4023-B6DB-D7987FDA4C43Q35879749-350ABDA4-6417-4F38-92FA-A359334F0B5DQ35934980-DEF3D785-FE3B-479F-BCF8-4AF6F0E0D7ECQ36450325-5A351C2A-DC10-40B0-A4BF-42382D02F7FCQ37373617-EF026E9D-62EF-4D19-BDE4-93313A1E9D88Q37406396-48741118-FC71-4E2D-9D2F-C238B3635841Q37409337-517D308A-662C-4853-BFAF-13D845131998Q38841887-ED0BDF8B-6BA8-48A5-BCA4-BD3650A417A3Q38844899-746AA646-6C7E-4FF7-9BAF-BA895537BAC6Q39183212-874F2FF5-681E-43AA-B54B-DA909F285009Q39230013-DC82BD4A-1A98-4A4F-947A-7B1E4AC34636Q40130706-FC582893-7BEE-4C60-9EE8-C4517D786489Q40356203-0BEC91B3-C5F8-4EEA-9603-6D84DC08CDAFQ40559371-5390C0DA-0630-42EF-A98C-7E7ED84609E5Q40663220-09C27658-91B6-4230-A62E-39670BD5ACD8Q40677243-04872FE0-3D12-4E8D-A7F8-FE3387378C35Q41372468-004FF9C7-1C68-44B7-9EAD-C7D1B25E9B8FQ41633774-B804BD4C-5F17-4EF7-BBC2-E2714397A557Q41641450-179C6C66-5365-48BE-873A-FA9A65461222Q41674287-655FE883-E3E0-4439-AB63-0B8016720365Q42246427-A9628EC9-7383-4D42-9A0A-0ED05AD7CFDCQ46304940-DDBDB34B-EB01-4BF4-B8A9-5347D10796BDQ46703864-3DC1F065-E720-4873-9D8B-F0A11C4E12A9Q47133313-BD4FD87F-4C58-4368-8725-7E97303100F2Q47748447-3002F34E-7FB1-4225-A61E-03E094FAD9B8Q48247281-0F833774-C404-4BBC-A42A-0AFEA5BE80BFQ51495132-505FB6DE-2404-45C4-AE6A-CAC372246517Q55024612-0E082BE5-A64D-4C9F-9CF2-4491BDB1FA78Q58602742-87473619-E95C-4E13-8858-21EA190B1757Q58693923-9A4899C7-4E34-4D0A-AEDF-8D62D90E2205
P2860
Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 January 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Structure and function of OprD ...... resistance to novel therapies.
@en
Structure and function of OprD ...... resistance to novel therapies.
@nl
type
label
Structure and function of OprD ...... resistance to novel therapies.
@en
Structure and function of OprD ...... resistance to novel therapies.
@nl
prefLabel
Structure and function of OprD ...... resistance to novel therapies.
@en
Structure and function of OprD ...... resistance to novel therapies.
@nl
P2093
P2860
P921
P1476
Structure and function of OprD ...... resistance to novel therapies.
@en
P2093
Bryan J Williams
Can-Mao Xie
Timothy S Blackwell
Yi-Feng Luo
P2860
P356
10.1016/J.IJMM.2011.10.001
P577
2012-01-05T00:00:00Z